-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC
As the first study to establish the role of immunotherapy in this setting, Dr. David R. Spigel says consolidation durvalumab will become the new standard of care for this population.
-
MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination
Compared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress.
-
Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?
In a recent interview, Dr. Lecia V. Sequist, a member of the team behind the Sybil AI algorithm, discusses how technology may soon be able to predict who will develop lung cancer.
-
FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm
During the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC.
-
Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC
In light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting.
-
Should Biomarkers Be Used in the Clinical Management of ES-SCLC?
During a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space.
-
Debaters Argue Merits of Surgery in Malignant Meso in Light of MARS2 Data
Surgeon Erin Gillaspie, MD, said surgery still has a role in the treatment of mesothelioma while medical oncologist Hedy Kindler, MD, said newer systemic therapies make surgery obsolete in this space.
-
Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question
Dr. Mark Kris, who leads the IASLC Pathologic Response Project, recently provided an update on efforts to collect data to confirm whether pathologic complete response can predict long-term outcomes.
-
Multidisciplinary Team to Chair 2025 World Conference
Drs. Umberto Malapelle, Jarushka Naidoo, Isabelle Opitz, and Noemí Reguart will lead WCLC when it returns to Barcelona September 6-9, 2025.
-
Abstract Submissions, Reviewer Workshop Applications Open for WCLC
The 2024 World Conference on Lung Cancer may still be months away, but with deadlines approaching, now is the time to submit scientific abstracts and applications for the JTO manuscript reviewer workshop.